Serotonin antagonist and reuptake inhibitor
Class of drug From Wikipedia, the free encyclopedia
Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also antagonize α1-adrenergic receptors. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds.
![]() | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|

List of SARIs
Summarize
Perspective
This section needs additional citations for verification. (April 2025) |
Marketed
Commercially available serotonin antagonist and reuptake inhibitors include etoperidone (Axiomin, Etonin),[citation needed] lorpiprazole (Normarex),[citation needed] mepiprazole (Psigodal),[citation needed] nefazodone,[1]: 586f [2]: 572f utility complicated by life-threatening idiosyncratic hepatotoxicity[1]: 305f (Serzone, Nefadar),[citation needed] and trazodone[2]: 565f [1]: 586f (Desyrel).[1]: 554
Never marketed
- lubazodone (YM-992,[clarification needed] YM-35995[clarification needed]) – a SARI that, as of this date,[when?] had not come to market.[citation needed]
Miscellaneous
- vilazodone (Viibryd) – a related drug not fitting into this class, as it acts solely as a 5-HT1A receptor partial agonist, but not as a serotonin antagonist;[citation needed] generally labeled as serotonin modulator and stimulator.[citation needed]
- vortioxetine (Trintellix) – another closely related drug generally labeled as a serotonin modulator and stimulator.[citation needed]
- niaprazine (Nopron) – a related drug that does not inhibit the reuptake of serotonin or other monoamines.[citation needed]
- medifoxamine (Clédial, Gerdaxyl) – a serotonin–dopamine reuptake inhibitor and 5-HT2A and 5-HT2C receptor antagonist,[3][non-primary source needed] although not grouped as such.[citation needed]
Pharmacology
Summarize
Perspective
Binding profiles
The binding profiles of SARIs and some metabolites in terms of their affinities (Ki, nM) for various receptors and transporters are as follows:[4]
Compound | SERT | NET | DAT | 5-HT1A | 5-HT2A | 5-HT2B | 5-HT2C | 5-HT3 | 5-HT6 | 5-HT7 | α1 | α2 | D2 | H1 | mACh | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Etoperidone | 890 | 20,000 | 52,000 | 85 | 36 | ND | ND | ND | ND | ND | 38 | 570 | 2,300 | 3,100 | >35,000 | |
Hydroxynefazodone | 165–1,203 | 376–1,053 | ND | 56–589 | 7.2–34 | ND | ND | ND | ND | ND | 8.0–145 | 63–2,490 | ND | ND | 11,357 | |
mCPP | 202–432 | 1,940–4,360 | ND | 44–400 | 32–398 | 3.2–63 | 3.4–251 | 427 | 1,748 | 163 | 97–2,900 | 106–570 | >10,000 | 326 | >10,000 | |
Nefazodone | 200–459 | 360–618 | 360 | 80 | 26 | ND | 72 | ND | ND | ND | 5.5–48 | 84–640 | 910 | ≥370 | >10,000 | |
Trazodone | 160–367 | ≥8,500 | ≥7,400 | 96–118 | 20–45 | 74–189 | 224–402 | >10,000 | >10,000 | 1,782 | 12–153 | 106–728 | ≥3,500 | 220–1,100 | >10,000 | |
Triazoledione | ≥34,527 | >100,000 | ND | 636–1,371 | 159–211 | ND | ND | ND | ND | ND | 173 | 1,915 | ND | ND | >100,000 | |
Values are Ki (nM). The smaller the value, the more strongly the drug binds to the site. For assay species and references, see the individual drug articles. Most but not all values are for human proteins. |
These drugs act as antagonists or inverse agonists of the 5-HT2A, α1-adrenergic, and H1 receptors, as partial agonists of the 5-HT1A receptor,[5] and as inhibitors of the transporters. mCPP is an antagonist of the 5-HT2B receptor, an agonist of the 5-HT1A,[5] 5-HT2C, and 5-HT3 receptors,[6][7] and acts as a partial agonist of the human 5-HT2A[8] and 5-HT2C receptors.[9]
See also
References
Wikiwand - on
Seamless Wikipedia browsing. On steroids.